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Introduction
Fetal parvovirus B19 infection is a congenital disor-
der that is characterized by nonimmune hydrops,
ascites, pleural effusion, hypertrophic cardiomyopathy,
placentomegaly, ventriculomegaly, and other findings
caused by transplacental transmission of parvovirus to
the fetus [1,2]. Congenital infection rates vary depend-
ing on the prevalence in the community. Approximately
50% to 75% of adult women are immune. Maternal
infection with parvovirus B19 is estimated to occur in
0.25–6% of susceptible pregnancies [1]. Transplacen-
tal transmission can occur any time during pregnancy.
The risk for congenital infection from an infected
mother to her unborn baby is between 10% to 35%
and is highest in the first and second trimesters [1,3].
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SUMMARY
Objective: In nonimmune pregnant woman, the primary infection with parvovirus B19 may lead to transplacen-
tal transmission to the fetus with variable outcomes, including congenital anemia, hydrops fetalis, fetal death
or spontaneous resolution.
Case Report: In the first case, a 28-year-old woman, gravida 2, para 1, whose fetus was found to have left-sided
pleural effusion on a sonogram at 29 weeks of gestation. A sample of aspirated pleural fluid was positive for
parvovirus B19 by polymerase chain reaction. Cordocentesis showed fetal hemoglobin level of 5.0 g/dL. Intra-
peritoneal transfusion (IPT) was performed, because access to the fetal circulation was difficult. Thirty milliliters
of group O, Rh-positive packed red cells were transfused into the peritoneal cavity. A non-hydropic baby weigh-
ing 2,680 g was delivered at 33 weeks of gestation. The neonate’s complete blood count examination showed a
hemoglobin level of 16.3 g/dL. The newborn baby was discharged in stable condition. In the second case, a 31-year-
old woman, gravida 2, para 1, whose fetus was found to have ascites, hypertrophic cardiomyopathy, and placen-
tomegaly on a sonogram at 23 weeks of gestation. An amniotic fluid sample was positive for parvovirus B19 DNA
by polymerase chain reaction. Fetal ascites and hypertrophic cardiomyopathy gradually resolved after maternal
iron supplementation and 2 weeks of intrauterine digitalization therapy. A healthy infant weighing 3,198 g was
delivered at 37 weeks of gestation. The neonate’s complete blood count examination showed a hemoglobin level
of 10.3 g/dL.
Conclusion: Termination of pregnancy is rarely indicated, because B19 virus is not teratogenic. Although
intravascular transfusion offers obvious theoretical advantages, in some cases in which access to the fetal circu-
lation is difficult or impossible, IPT should be performed combined with appropriate medical treatment. Thus,
there is still a place for IPT in modern management of the severely anemic fetus, and this technique should not
be neglected. [Taiwan J Obstet Gynecol 2007;46(4):417–422]
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■ CASE REPORT ■
The average time from diagnosis to resolution is about
6 weeks [1].
We describe two cases of congenital fetal parvovirus
infection that were timely diagnosed by sonography and
viral DNA polymerase chain reaction (PCR) examina-
tion and managed successfully with intraperitoneal
transfusion (IPT) and medical treatment.
Case Report
Case 1
A 28-year-old woman, gravida 2, para 1, was referred
to our hospital at 29 weeks of gestation because of fetal
pleural effusion. Pertinent medical history and obstetric
history included an alpha-thalassemia trait and recent
flu-like symptoms transmitted from her 4-year-old
febrile child. A Doppler ultrasonographic examination
(Voluson 730 Expert; GE Medical Systems, Austria)
showed a massive left-sided pleural effusion (Figure 1A),
hydrocele, polyhydramnios (amniotic fluid index,
38 cm), and bulky placenta (5.54 cm). Venous Doppler
waveform analysis revealed a high time-averaged
velocity of 30 cm/s without ominous sign of absence
or reversal of atrial systolic blood flow velocity in 
the ductus venous. Thoracocentesis was performed,
and 50 mL of blood-tinged pleural fluid was aspirated
from the left pleural cavity. Pleural fluid examination
showed red blood cells (RBCs) of 70,000/mm3, white
blood cells (WBCs) of 24,300/mm3 (lymphocyte/
neutrophil ratio, 99:1), and Pandy’s test of 4+. A sam-
ple of aspirated pleural fluid was positive for parvovirus
B19 by PCR. The karyotype was 46,XY. Percutaneous
umbilical blood sampling showed hemoglobin level of
5.0 g/dL. Maternal hemoglobin level was 6.9 g/dL
(hematocrit, 23.7%). IPT was performed at 31 weeks of
gestation, because access to the fetal circulation was
difficult. The patient was sedated with an intravenous
narcotic (pethidine) and a tranquilizer. After aseptic
preparation, a 20-gauge percutaneous transhepatic
cholangiography (PTC) needle (Hakko, Japan) was
inserted into the fetal abdominal cavity under direct
ultrasound guidance. Proper needle placement was
verified by injecting a small amount of saline solution
and observing fluid layering in the peritoneal cavity.
Thirty milliliters of group O, Rh-positive packed RBCs
were injected directly through the PTC needle in
aliquots of 10 mL at an average of 5–10 mL per minute,
taking 2 to 5 minutes for each aliquot (Figure 1B).
Transient bradycardia was observed after 15 mL of
RBCs were transfused, and the IPT was discontinued
for 2 minutes before giving the full amount of blood
calculated as necessary after the fetal heart rate
returned to normal baseline level. The amount of 
pleural effusion was increased after IPT procedure. A
repeat thoracocentesis was performed to decrease
lung compression, and 70 mL of darkish pleural 
fluid was aspirated (RBCs, 290,000/mm3; WBCs,
15,800/mm3).
The patient received 1 week’s intrauterine digitaliza-
tion therapy with digoxin 0.25 mg 12 hourly (maternal
digoxin, 1.51 ng/mL) for impending fetal heart failure
signs. Preterm labor occurred at 33 weeks of gestation,
and she spontaneously delivered a non-hydropic male
baby weighing 2,680 g with Apgar scores of 1 and 
6 at 1 and 5 minutes, respectively. The neonate’s com-
plete blood count examination showed a hemoglobin
level of 16.3 g/dL. The newborn baby was sent to the
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Figure 1. (A) Hydrothorax associated with fetal parvovirus infection. Axial scan of the thorax at 29 weeks shows a large left
pleural fluid collection which shifts the heart to the right. F = pleural fluid; H = heart; L = lung. (B) Sonographic image depicts
intraperitoneal transfusion. Thirty milliliters group O, Rh-positive packed red cells were injected into the free peritoneal cavity,
as shown by ultrasound outlining the hypoechoic shadow surrounding the liver and small bowel. B = red cells; F = pleural fluid;
Li = liver; Lu = lung.
neonatal intensive care unit for further care. Thoracic
tube was inserted for drainage of pleural fluid. The
newborn baby was hospitalized for 2 weeks and was
discharged in stable condition.
Case 2
A 31-year-old woman, gravida 2, para 1, was referred to
our hospital, because her fetus was found to have ascites,
hypertrophic cardiomyopathy, and placentomegaly on
a sonogram at 23 weeks of gestation. Pertinent med-
ical history and obstetric history included recent flu-
like symptoms transmitted from her 16-month-old
febrile child. A Doppler ultrasonographic examination
showed a small amount of ascites, hypertrophic
cardiomyopathy with interventricular septum thick-
ness measuring 6.4 mm, and bulky placenta (Figure 2).
Intrahepatic portion of the umbilical vein was markedly
dilated. The umbilical artery Doppler systolic/diastolic
ratio measurement was 3.0 without pulsatile flow in
the umbilical vein. An amniotic fluid sample was posi-
tive for parvovirus B19 DNA by PCR. The chromosome
karyotype was a normal 46,XX. Intrauterine transfusion
(IUT) was arranged but was halted, because the ascites
and hypertrophic cardiomyopathy gradually resolved
after maternal iron, folic acid and vitamin B complex
supplementation therapy and 2 weeks of intrauterine
digitalization therapy with digoxin 0.25 mg 12 hourly
(maternal digoxin, 1.22 ng/mL).
A healthy female infant weighing 3,198 g was deliv-
ered vaginally at 37 weeks of gestation. The neonate’s
complete blood count examination showed a hemo-
globin level of 10.3 g/dL (hematocrit, 31.2%) and
platelet count of 383,000/µL. Neonatal echocardiog-
raphy showed unremarkable finding except for the
patent foramen ovale and patent ductus arteriosus.
The newborn baby was hospitalized for 3 days and 
discharged in stable condition.
Discussion
Erythema infectiosum (infectious redness) is also
known as “slapped-cheek” disease or “fifth disease”.
The name fifth disease stems from that when diseases
causing childhood exanthemata (rashes) were enumer-
ated, it was fifth on the list. Erythema infectiosum is
caused by a virus called parvovirus B19. The virus is hor-
izontally transmitted from one person to another via
airborne droplets from the nose and throat, for exam-
ple when coughing or sneezing. Parvovirus B19 infection
is common in school-aged children and younger chil-
dren who attend day-care facilities. Seropositivity rates
are 5–10% among young children (aged 2–5 years),
increasing to 50% by age 15 years and 60% by age 30
years. These results suggest that parvovirus B19 infection
is an occupational risk for female teachers and day-care
providers who have contact with greater numbers of ill
children [4].
The parvovirus may be small, but they are mighty.
The virus has a tropism for rapidly dividing erythrocyte
precursors, particularly pronormoblasts and normo-
blasts, wherein they replicate to high titers, destroying
infected cells [1,2]. Thus, no reticulocytes are available
to replace abnormal short half-life aging or damaged
erythrocytes, as they are cleared by the reticulo-
endothelial system. The fetus may be especially vulner-
able to anemia due to parvovirus B19 infection because
of the short-lived RBCs and a possible ineffective
immune response that can lead to chronic infection.
Rare reports in the literature state that parvovirus 
B19 may infect other cell types, causing encephalitis
and myocarditis [1,2,5]. Additionally, Nagel et al [6]
reported abnormal neurodevelopmental status in five
of 16 survivors that was not related to the severity of
fetal anemia and acidemia. They hypothesized that fetal
parvovirus B19 infection may induce central nervous
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Figure 2. (A) Axial scan of the abdomen at 23 weeks shows a small amount of ascites (arrow) and mildly thickened placenta (P).
(B) Four-chamber view shows thickened interventricular septum 0.64 cm (arrows) and hypertrophic ventricular wall.
system damage. Long-term postnatal investigation is
warranted, especially in the presence of clinical symp-
toms or developmental delay.
Occasionally, the virus infects leukocytes (especially
neutrophils) and megakaryocytes [2]. Although par-
vovirus B19 infection may manifest with pancytopenia, it
is not believed to contribute significantly to true aplastic
anemia. However, in patients with hemoglobinopathies
or hemolytic anemias, in whom the duration of erythro-
cyte survival is decreased, a decrease in the reticulocyte
count to less than 1% may precipitate an aplastic crisis.
Parvovirus B19 is the only known infectious cause of
aplastic crisis [2].
During the first trimester, fetuses with parvovirus
B19 infection can present with increased nuchal trans-
lucency. In the second and third trimesters, fetal infec-
tion by parvovirus B19 can be suspected using
ultrasound, with the presence of fetal hydrops, ascites,
pleural or pericardial effusion, skin thickening, hyper-
trophic cardiomyopathy, hepatosplenomegaly, hydro-
cephalus, microcephaly, intracranial calcifications,
placentomegaly, and amniotic fluid volume disorders
[1]. Fetal anemia is associated with a hyperdynamic
circulation; therefore, it can be predicted with Doppler
measurement of the middle cerebral artery peak sys-
tolic velocity in pregnancies complicated by parvovirus
B19 infection by increased values of velocities prior to
the appearance of sonographic signs of hydrops [7].
Furthermore, cordocentesis allows precise assessment
of fetal anemia, which can then be corrected by IUT.
Absence or reversal of atrial systolic blood flow velo-
city in the ductus venosus and pulsatile flow in the
umbilical vein offers the best prediction of perinatal
critical outcomes due to end-stage heart failure and
regurgitation secondary to tricuspid insufficiency. The
outcome proved favorable in the majority of fetuses,
even in those that were severely anemic. The overall rate
of parvovirus B19-related fetal death has been esti-
mated as between 4% and 17%, with a peak frequency
before 20 weeks of gestation [1,3].
Specific diagnosis can be made by the following
methods [2]. If a pregnant woman is exposed to 
parvovirus B19, obtain a serologic examination to test
for maternal parvovirus B19-specific IgG and IgM as
soon as possible. Positive IgG and IgM results indicate
infection within the last 7–120 days (possible risk to
fetus). Negative IgG and positive IgM results indicate
acute infection (higher risk to fetus). Cordocentesis
can be performed to test for fetal blood parvovirus
B19-specific IgM. PCR is a more useful clinical tool to
diagnose for infection and detects if any of the viral
DNA is present in the blood, amniotic fluid and other
body fluids on both fresh and paraffin-embedded 
tissues. A positive result is indicative of viremia/infec-
tion. Electron microscopy can also identify parvovirus
B19 virus in tissues.
Because the major fetal manifestation of parvovirus
infection is anemia, IUT should be considered if a cor-
docentesis shows a fetal blood sample hemoglobin
level of < 10 g/dL. In 1963, Liley successfully performed
the first IPT on a severely sensitized erythroblastotic
infant in utero, and in doing so, created new horizon
in obstetric care [8]. For more than 20 years, the tra-
ditional method for performing transfusion in utero has
utilized the IPT approach under direct ultrasound guid-
ance [8–11]. Proper needle placed freely in the fetal
peritoneal cavity should be verified by aspirating ascitic
fluid in the hydropic fetus or by injecting a small amount
of saline solution and observing the layering of fluid
space in the peritoneal cavity in the non-hydropic fetus.
Otherwise, injection into retroperitoneal tissue, abdom-
inal viscera, soft tissues and so on, would be disastrous.
Washed and irradiated group O, Rh-positive packed cells,
which have been cross-matched against the mother’s
blood, are injected directly through the needle in al-
iquots of 10 mL at an average of 5–10 mL per minute,
taking 2 to 5 minutes for each aliquot. The fetal heart
rate should be monitored throughout the procedure.
The fetus usually tolerates these infusion rates without
difficulty. However, if persistent bradycardia or fetal
cardiac irregularity is observed, IPT should be discon-
tinued before giving the full amount of blood calcu-
lated as necessary. A second transfusion is given 10 to
12 days after the first transfusion, and subsequent
transfusions are administered at intervals of 3 to 4 weeks
until the fetus has reached 33 weeks of gestation or
greater [8,10]. While IPT is of minimal hazard to the
mother, it may pose a potential hazard to the fetus. In
the Winnipeg ultrasound era, a traumatic-death-per-
procedure rate of 3.7% was reported in severely ery-
throblastotic fetuses [10]. However, Watts et al [11]
reported that no immediate transfusion-related death
occurred for the 77 IPTs in 35 pregnancies.
The amount of transfused blood necessary to cor-
rect for fetal anemia was determined by the formula
proposed by Rodeck et al [12]: V (Hct3 – Hct1)/Hct2,
where V = estimated fetoplacental volume, Hct1 = the
pretransfusion hematocrit, Hct2 = the Hct of the trans-
fused blood, and Hct3 = the desired Hct. Another trans-
fusion volume formula is: gestation in weeks minus
20 × 10 mL [8,9,11]. However, in case 1, we limited the
volume to the smallest possible volume of 20–25 mL/kg
of the estimated fetal body weight according to gesta-
tional age to minimize the stress to the fetal cardiovas-
cular system, which could be aggravated by parvovirus
B19 infective myocarditis [13]. The more severe the
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hydrops, the lesser IUT will be well tolerated. Fetal trans-
fusions are rarely carried out later than 33 to 34 weeks
of gestation, as delivery during that gestation period
carries a 95% chance of infant survival. The decision to
manage case 2 conservatively was based on evidence
of spontaneous resolution of ascites and hypertrophic
cardiomyopathy after an appropriate medical therapy,
when compared with the initial sonographic findings
at the source of referral.
Erythrocytes injected into the fetal peritoneal cavity
are absorbed intact via the subdiaphragmatic lymphat-
ics, which drain into the right lymphatic duct and hence
into the systemic circulation [8,10]. Absorption of red
cells in the fetus without ascites takes 8 to 12 days. If hy-
drops is present, the absorption may be erratic. In some
cases, it is excellent, while in others, it is poor; particu-
larly in the moribund fetus with no breathing movement,
the absorption is negligible. The reversal of hydrops
may occur if absorption of red cells is adequate. First,
the hemoglobin level rises to correct anemia. Second,
erythropoietin production drops and hepatic erythro-
poiesis diminishes. This in turn causes a fall in portal
and umbilical venous pressures and improves hepatic
circulation and hepatocyte function with the resultant
increase in albumin levels [8].
Since absorption of red cells from the peritoneum
is erratic in the presence of ascites, fetal ascites should
be aspirated before IPT is performed. Although the intra-
vascular approach offers obvious theoretical advantages
for these hydropic fetuses, for cases in which access to
the fetal circulation is difficult or impossible because
of technical reasons, IPT should be performed. Thus,
there is still a place for IPT in modern management of
the severely anemic fetus, and this technique should
not be neglected.
There seem to be two different mechanisms involved
in the pathophysiology of nonimmune hydrops fetalis:
anemia and heart failure [14]. The low hemoglobin
level was not significantly related to the outcome
[6,14]. A simple fetal hematologic evaluation is unable
to provide new insights on parameters that may be 
of prognostic value. Therefore, the role of IUT in the
management of in utero parvovirus B19 infection may
be different from that of immune hydrops. It is possi-
ble that parvovirus B19-induced myocarditis could be
an associated deleterious event, leading even to heart
failure and death. There is even a report of terminal
cardiac heart failure in a third-trimester fetus, which
had a successful transplant postnatally [5]. Therefore,
Forestier et al [14] suggested that IUT should be con-
sidered only in fetuses with severe anemia (Hct < 15%),
because the condition can be a cause of fetal death.
Use of intrauterine digitalization therapy to treat fetal
hypertrophic cardiomyopathy has been attempted as
a palliative treatment in our case with good effect
[15,16]. Intravenous immunoglobulins therapy have
been successfully used in postnatal patients. It has
been shown to be effective in resolution of viremia and
improvement in red cell indices [2]. Spontaneous reso-
lution of fetal hydrops without intervention has also
been documented [13]. In view of these therapeutic
options, termination of pregnancy is rarely indicated,
because parvovirus B19 is not teratogenic.
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